I'm double dipping here. Last time I tipped this one was just prior to FDA approval for their Remplir product. Now I'm tipping pre-US sales for Remplir and also pre-TGA approval for their tendon repair product.
Orthocell SP: $1.27 MC around $310m SOI around 242m
Orthocell has Striate for dental bone and tissue repair and Remplir for nerve regeneration currently in the market in quite a number of countries. They also have an application with the TGA for approval of SmrtGraft which is for tendon repair. Apparently this approval should be granted some time in June. In addition to this, OCC recently received FDA approval for Remplir in the US (in early April) and is expecting first sales before the end of June. Currently the SP is very attractive at less than $1.30 and well positioned for a decent gain if one or both of the expected announcements are made this month.
